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Abstract
DNA hypermethylation is a common epigenetic abnormality in cancer and may serve as a useful marker to clone cancer-
related genes as well as a marker of clinical disease activity. To identify CpG islands methylated in prostate cancer, we used
methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) on prostate cancer cell
lines. We isolated 34 clones that corresponded to promoter CpG islands, including 5 reported targets of hypermethylation in
cancer. We confirmed the data for 17 CpG islands by COBRA and/or pyrosequencing. All 17 genes were methylated in at
least 2 cell lines of a 21-cancer cell line panel containing prostate cancer, colon cancer, leukemia, and breast cancer. Based
on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and
NSE1 are candidate biomarkers for prostate cancer (methylation range 50%–85%). The combination of NSE1 or SPOCK2
hypermethylation showed a sensitivity of 80% and specificity of 95% in differentiating cancer from normal. Similarly NKX2-5,
SPOCK2, SLC16A12, DPYS and GALR2 are candidate biomarkers for colon cancer (methylation range 60%–95%) and GALR2
hypermethylation showed a sensitivity of 85% and specificity of 95%. Finally, SLC16A12, GALR2, TOX, SPOCK2, EGFR5 and
DPYS are candidate biomarkers for breast cancer (methylation range 33%–79%) with the combination of EGFR5 or TOX
hypermethylation showing a sensitivity of 92% and specificity of 92%. Expression analysis for eight genes that had the most
hypermethylation confirmed the methylation associated silencing and reactivation with 5-aza-29-deoxycytidine treatment.
Our data identify new targets of transcriptional silencing in cancer, and provide new biomarkers that could be useful in
screening for prostate cancer and other cancers.
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Introduction
Prostate cancer is one of the most common malignancies and the
second leading cause of cancer death among men in the United
States [1]. The molecular mechanisms of prostate cancer develop-
ment and progression remain poorly understood. Genetic and
epigenetic alterations contribute to prostate cancer formation, as
with most other cancers. DNA hypermethylation is the most
common epigenetic abnormality in cancer. Hypermethylation of
CpG islands in promoter regions usually results in gene silencing,
and several tumor suppressor genes are hypermethylated in their
promoter regions in human cancers, which is thought to contribute
to tumorigenesis [2,3]. Therefore, DNA hypermethylation may
serve as a useful target to clone novel tumor suppressor genes. In
prostate cancers, inactivation by aberrant methylation has been
reported for many genes, such as APC [4], HIC1 [5], RARb2[ 6 ] ,
GSTP1 [7], CDH1 [8], MDR1 [9] and RASSF1A [10].
Although the list of aberrantly methylated genes is expanding,
only a few genes show promise as tumor biomarkers for early
diagnosis and risk assessment of prostate cancer. Thus, large-
(genome wide) scale screening of aberrant methylation of CpG
islands is needed to identify prostate-specific epigenetic markers.
To identify CpG islands differentially methylated in prostate
cancer and other cancers, we performed methylated CpG island
amplification (MCA) coupled with representational difference
analysis (RDA) [11]. Applying this method to prostate cancer, we
isolated 34 clones that corresponded to promoter CpG islands.
Several are promising biomarkers for prostate and other cancers.
Materials and Methods
Cell lines and tissue samples
Cell lines used in this study were obtained from the American
Type Culture Collection (Manassas, VA). All cell lines were
cultured in recommended medium in the presence of 10% FBS in
a humidified atmosphere containing 5% CO2 at 37uC. Samples of
colon cancer paired with normal colon mucosa and samples of
breast cancer paired with normal breast were obtained from
established tissue banks at the University of Texas M. D. Anderson
Cancer Center (Houston, TX). Samples of prostate cancer and
normal prostate were obtained from Baylor College of Medicine
(Houston, TX). Microdissection was employed to isolate prostate
cancer cells and non-neoplastic prostate epithelial cells. SVHUC,
normal urothelial cells, immortalized in vitro by SV40 was a gift
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DNA was isolated by extraction buffer with 100 mg/ml proteinase
K (Sigma, St. Louis, MO) and standard phenol-chloroform
methods. All samples were collected from consenting patients
according to institutional guidelines.
MCA/RDA
MCA/RDA was performed as described [11]. Briefly, 5 mgo f
DNA was digested with SmaI followed by XmaI (New England
Biolabs, MA). The restriction fragments were ligated to adapters
and amplified by PCR. The reaction mixture was incubated at
72uC for 5 min and at 95uC for 3 min, and then was subjected to
25 cycles of 1 min at 95uC and 3 min at 77uC followed by a final
extension of 10 min at 77uC. MCA amplicons from the prostate
cancer cell lines DU145, PC3 and LNCaP were mixed and used as
the tester for RDA. MCA amplicons were generated from a
mixture of normal blood and normal colon mucosa DNA was used
as the driver. Two rounds of RDA subtractive hybridization were
performed on these MCA amplicons using different adapters,
JMCA and NMCA. After the third round of subtractive
hybridization and selective amplification, the RDA products were
cloned into a TOPO TA cloning vector (Invitrogen, Carlsbad,
CA). Sequence analysis was carried out with an ABI PRISM 377
DNA sequencer (Applied Biosystems, Foster City, CA) at the DNA
sequencing core facility at the University of Texas M. D. Anderson
Cancer Center.
DNA bisulfite treatment
After DNA extraction, DNA was treated with bisulfite as
reported previously [12]. Two mg of genomic DNA were
denatured by 0.2 M NaOH at 37uC for 10 minutes, followed by
incubation with freshly prepared 30 ml 10 mM hydroquinone
(Sigma) and 520 ml 3 M sodium bisulfite (pH 5.0) at 50uC for
16 hours. Bisulfite-converted DNA was purified with a Wizard
miniprep Column (Promega) and incubated with 0.3 M NaOH for
5 minutes at room temperature. DNA was then precipitated with
ammonium acetate and ethanol, washed with 70% ethanol, dried
and dissolved in 40 ml distilled water. We used SssI methylase
(New England Biolabs) - treated normal leukocytes DNA as a
positive control for methylation studies.
Combined bisulfite restriction analysis (COBRA) and
Pyrosequencing
We used bisulfite-PCR followed by COBRA [13] and/or
Pyrosequencing [14] to analyze the methylation status of cell lines
and patient samples. PCR reactions were carried in 50 ml reaction
volume; including 2 ml bisulfite treated DNA, 2 mM MgCl2,
0.25 mM dNTP, 1 unit Taq polymerase, 16 mM (NH4)2SO4,
67 mM Tris-HCl (pH 8.8), 1 mM 2-mercaptoethanol and
100 nM primers. COBRA primers and restriction enzymes for
digestion are shown in Table 1. PCR products after restriction
enzyme digestion were separated in 5% nondenaturing polyacryl-
amide gels, followed by densitometric analysis to obtain quanti-
tative methylation levels. Densitometric analysis was performed
using a BioRad Geldoc 2000 digital analyzer equipped with the
Quantity One version 4.0.3 software (BioRad, Hercules, CA).
SLC16A12, TOX, GALR2, TFAP2C and PAX9 were analyzed
by COBRA and/or quantitated using the PSQ HS 96
Pyrosequencing System (Pyrosequencing Inc, Westborough, MA)
[14]. In order to determine the quantitative accuracy of the
COBRA and pyrosequencing assays, we tested DNA from normal
leukocytes spiked with 0%, 33%, 67% and 100% methylated DNA
obtained by SssI methylase treatment.
RNA purification and reverse transcription-PCR (RT-PCR)
Gene expression was analyzed by RT-PCR. Total RNA
obtained from different cell lines was isolated using the TRIZOL
reagent (Molecular Research Center, Inc., Cincinnati, OH).
Reverse transcription reactions were performed using MMLV-
RT (Takara) and random hexamers on 5 mg of total RNA per
reaction according to the manufacturer’s protocol and amplified
by PCR using primers shown in Table 1. GAPDH mRNA was
used as an internal control.
Treatment with 5-Aza-29-deoxycytidine (5-AzadC) and/or
Trichostatin A (TSA)
Cancer cells were split 12–24 h before drug treatment. Cancer
cells were treated with 5-AzadC (Sigma) and TSA (ICN, Irvine,
CA) either alone or in combination. Cells were exposed
continuously to 5-AzadC (1 mmol/L refreshed daily) for 3 days
or to TSA (300 nmol/L) for 20 hours. For combined treatment,
cells were cultured in the presence of 5-AzadC (1 mmol/L
refreshed daily) for 3 days and exposed on the third day (24 hours)
in combination with TSA (300 nmol/L). Mock-treated cells were
cultured similarly.
Statistical Analysis
Statistical analyses were performed using Prism 4 software
(GraphPad Software, Inc., San Diego, CA). The Pearson test was
used to determine correlations. The Fisher’s exact test and t-tests
were used to compare methylation in normal and cancer tissues.
We used a cut-off corresponding to average methylation in normal
tissues+2 standard deviation (sD) to call a cancer as methylation
positive (above the cut-off). Sensitivity, specificity and accuracy of
each individual or 2 combined candidate biomarkers were
calculated. Sensitivity was defined as the number of true-positive
(methylated in cancer) cases divided by the number of true-positive
plus false-negative (not methylated in cancer) cases and specificity
was defined as the number of true-negative (not methylated in
normal tissue) cases divided by the number of true-negative plus
false-positive (methylated in normal tissue) cases. The accuracy of
a test is measured by the area under the Receiver Operating
Characateristic (ROC) curve. All reported p values were 2-sided
and P,0.05 was considered statistically significant.
Results
Detection of Methylated CpG Islands Using MCA-RDA
To identify novel CpG islands aberrantly methylated in prostate
cancer, we used MCA-RDA [11]. RDA was performed on MCA
amplicons from a mixture of the prostate cancer cell lines DU145,
PC3 and LNCaP as a tester, and a mixture of normal colon
mucosa DNA from three different men and normal leukocytes
from two different men as a driver. After 2 rounds of RDA, PCR
products were cloned and DNA sequencing was performed on 198
randomly selected clones. Of the 198 clones, 17 corresponded to
repeats including Alu, 94 corresponded to non-CpG island DNA,
50 corresponded to non-promoter CpG islands and 37 corre-
sponded to 34 unique promoter associated CpG islands, as
revealed by BLAST (www.ncbi.nlm.nih.gov) and BLAT (geno-
me.ucsc.edu) searches. The homology of each unique promoter
associated clone, chromosomal location, and GenBank accession
numbers are summarized in Table 2. Five of the 34 clones
corresponded to genes previously reported as methylated in
cancer. Four of the clones corresponded to bi-directional
promoters. Chromosomal location of the clones appeared random
with no evidence of clustering (Table 2).
Novel Markers for Prostate Ca
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To confirm the accuracy of MCA-RDA, differential methyla-
tion was investigated by COBRA analysis [15] or pyrosequencing
for seventeen known genes (all except the 5 previouly known as
methylated). All the MCA-RDA clones related to the genes
analyzed in this study had CCCGGG sites on both sides consistent
with the MCA technique. The primers for COBRA or
pyrosequencing analysis were designed close to the promoter
region in each case (Figure 1). Figure 2 shows examples of the
Table 1. Primers used in this study.
COBRA
Sence Antisense PCR size
Restriction
Enzyme
NSE1 GAATTAAGGTTTTGGGGGATT CCCAAAACACCCCAATATAA 109 bp HpyCH4IV
TFAP2C GGGGTGGGTTTTAGTATTTGG CCAACCAATCCCAACCTAAC 224 bp HpaI
TFAP2E GGGTTTATGGAGGTAGGA AAAAACTACCATAACTTATCTCTTTA 179 bp HpaI
CDEP TTTTGTTTGGGGTTGTTT ACTCCCCCAAACTTAAATC 142 bp Hpy188I
NKX2-5 GAGAGTAGGGTTGGGGAATATG AACCCCTAACCCAATAACAAACT 236 bp BstUI
BTBD14A GGGAGAGTTTTYGGGTTTTT AAACCCAATCCAAACAACTTACA 238 bp RsaI
IRX5 GAGTAATTTTTGAGTTTAAGGTTTGG AACAACCAAAAACCAAATACCC 527 bp HpyCH4III
ETNK2 GAAGGGGGTATAGTTATTTTTAGTAG TAAATCATAAACTTCCCCTAACC 126 bp HinfI
GALR2 GGTTAGGAGGAGGAGTAAGAGA CTACACCCCTACCAAACTACAA 313 bp HpyCH4IV
DPYS TAGAATATTTGGGGTTTGAGTGT TTAAAATACCCTCCTACAAAATCC 200 bp HinfI
CLSTN1 AAATTGGGAGGATTTTAAGATTT CCCAAAACCCTTATCACTTC 385 bp HpyCH4IV
SPOCK2 GGGGTTTTGATTTTTGTAGTATTTT TTTCAAACAAATACATCTCCTAACC 165 bp RsaI
EGFR5 GAGTTGTTTTTAATTTGGATTTGTT CAACTATATTCCTAACCCCAAAA 121 bp HpyCH4IV
FOXN4 GGGTTTTTATTTTGGAAATGTA CCCTACCCTATAACTAACCCTTA 291 bp BstBI
TOX1 GTGGTTTGTTTAAGAAGAAGAGGA ACAAAACAACTCAAAATCTCCAAT 289 bp TaqI
SLC16A12 GGGGTATGGGGGTGGTTT ACCCAACCCAAACAAAACAAAT 397 bp Hpy188I
PAX9 GGAAAGTTTTTGTTTGGGAGTG AATAACATCAACAACCACCCAAT 284 bp HinfI
Pyro-sequencinig
Sense Antisence Sequencing primer
PAX9 TTTAGGTGGGGAGTTAGTTTGAAAGA U-ACCAATCCCAAAACAAACTACATAATAATTAA AAGGAGTTTTTTGGATTG
SLC16A12 TAGAGGGAGAGGTGGTTTAGGTGAT U-CACCCAAATTAAAATCCCAAACTC AAGGGTATTTTTTAAGGAAG
TOX GGGGATAATGAGAGTATGAAGTTATTTGT U-CCCTCACATCCCTTTATAATTTATTTAA GGAGGAGGTGGAGTAGG
DPYS TTAGTTTTTTAGGGGGGAGGAGT U-ACCCCCCAACTCTACCTCAAAC GTAGTATATGAGGTTAGGTTATAAAT
NKX2-5 AGAGTAGGGTTGGGGAATATGG U-CCCTCTCCTACCCCTTATACTCAA TAGGTGGGAGGTAGAA
SPOCK2 TAGAGGGAGGAGAGTTGAGGATAG U-TCCACCTAAAAAAATCTTAACTTCTACAATA GGAGGAGAGTTGAGGATAG
EGFR5 GGTTGGGGAAGTTAGTTGTAGAGG U-ACCCAAAACTACTCCCAACTTAAATC GGGAAGTTAGTTGTAGAGG
GALR2 GGGGTTAGGAGGAGGAGTAAGAGA U-ACCACTCCCCAACCCTTCC GGAGAGGTTGTTTTTAGTAG
TFAP2C GGTTTTAGGGGAGGAGTTATGATAAT U-CCCCCCAACAATATATCCTAA TTATGATAATTTTTTTTTTATTAAG
RT-PCR
Sense Antisence PCR size
GALR2 GCACTTCCTCATCTTCCTCA GACTGGCGGTAGTAGCTCAG 198 bp
DPYS CTGTACGAAGCCTTCTCTCG CCTTAGCTGCAGACTTGCTC 247 bp
TPAP2C CCCACTGAGGTCTTCTGCTC AGAGTCACATGAGCGGCTTT 245 bp
NSE1 CAGGAGACTTTAAAGGAGTTTGG TCATCATCCGAGAAGAAGTAGG 206 bp
TFAP2E GACCTGCAGGCAATGGAC CCTTGTACTTGGACGTTGAGC 205 bp
CDEP GGTACGATGATCAAGATGGAGA CGTGGACTTTAAACTGATTGGA 223 bp
NKX2-5 CCCTAGAGCCGAAAAGAAAGA GGTTCTGGAACCAGATCTTGAC 251 bp
SPOCK2 GAGACGAAGTGGAGGATGACTA CTTGCAGATGGAGTCTTTGTTT 227 bp
GAPDH ACAGTCAGCCGCATCTTCTT GACAAGCTTCCCGTTCTCAG 259 bp
Y=CorT.
U=biotin labeled universal primer tag : 59-biotin-GGGACACCGCTGATCGTTTA.
doi:10.1371/journal.pone.0002079.t001
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digested with restriction enzymes that distinguish methylated from
unmethylated DNA after bisulfite treatment for COBRA assay
(Table 1). In order to determine the quantitative accuracy of the
COBRA and pyrosequencing assays, we tested both assays on
DNA from normal leukocytes, 2:1 (33%) mixture, 1:2 (67%)
mixture and fully methylated DNA (100%) obtained by SssI
treatment. The assays showed significant correlations between
predicted and measured values by pyrosequencing (GALR2,
Pearson r =0.98, P,0.001) and COBRA (SLC16A12, Pearson
r=0.99, P=0.008; GALR2, Pearson r=0.99, P=0.002). We also
compared data obtained by COBRA or pyrosequencing in 364
measurements, and found a high degree of correlation between the
two methods (Pearson r=0.939, n=364 pairs, P,0.001)
(Figure 2). Similarly, correlations between two different pyrose-
quencing assays were very high (Pearson r=0.977, n=458 pairs,
P,0.001). All of the 17 genes investigated were methylated in at
least 2 cell lines of a 21-cell line panel (summarized in Figure 3A
and Table S1). Sixteen of the 17 analyzed genes showed
hypermethylation in at least one of three prostate cancer cell
lines. Only TFAP2C did not display hypermethylation in any
prostate cancer cell line. For this gene, the MCA product was 2
Kb upstream of the promoter and COBRA showed methylation
close to the MCA product (data not shown) but not in the gene
promoter. Individual cell lines varied in methylation frequency
from 5/17 (Hep3B) to 15/17 (RAJI) and colon cancer and
leukemia appeared to have the most methylation. Seven out of 17
genes analyzed in this study had methylation in the non-
Table 2. Hypermethylated promoter - associated CpG island clones isolated by MCA-RDA.
No. Gene name Bidirectional Locus Location* Previously Reported [reference]
1 ALX3 No 1p13.3 110324472–110324835 Yes [29]
2 TFAP2E No 1p34.3 35708094–35708319 No
3 CLSTN1 No 1p36.22 9818652–9818922 No
4 AW295421, BM809018 Yes 1q21.1 144745596–144745909 No
5 ETNK2 No 1q32.1 200852162–200852445 No
6 NSE1 No 2p24.3 14723003–14723236 No
7 AB029015 No 3p24.3 16900443–16900785 No
8 KIAA1729 No 4p16.1 10135303–10135580 No
9 BC048329 No 5q31.1 135556264–135556542 No
10 CDX1 No 5q32 149526986–149527183 Yes [30]
11 FLJ14166 (CCNJL) No 5q33.3 159671339–159671601 No
12 NKX2-5 (CSX) No 5q35.1 172593550–172593870 Yes [11]
13 AK128409 No 6p25.3 1565515–1565753 No
14 MOGAT3 No 7q22.1 100632085–100632363 No
15 TOX No 8q12.1 60193205–60193432 No
16 DPYS No 8q22.3 105548353–105548518 No
17 SCXA No 8q24.3 145460987–145461257 No
18 BTBD14A No 9q34.3 136211905–136212286 No
19 SPOCK2 (Testican-2) No 10q22.1 73517716–73517874 No
20 SLC16A12 No 10q23.31 91285295–91285471 No
21 FOXN4 No 12q24.11 108209604–108209916 No
22 FLT1 (VEGFR-1), CR600638 Yes 13q12.3 27966278–27966465 Yes [31]
23 CDEP (FARP1 ) No 13q13.2 97592455–97592835 No
24 PAX9 No 14q13.3 36202075–36202382 No
25 EGFR5 (C14orf27) No 14q21.1 37794235–37794429 No
26 IRX5, AF275804 Yes 16q12.2 53523634–53523826 No
27 GALR2 No 17q25.1 71581744–71581919 No
28 NFIC (AK129956) No 19p13.3 3414086–3414270 No
29 LOC126147 No 19p13.33 53869474–53869704 No
30 BX537419, BQ068319 Yes 19q13.43 63550508–63550666 No
31 GCX1 No 20q13.12 41978149–41978397 No
32 TFAP2C No 20q13.31 54634117–54634337 No
33 TIMP3 No 22q12.3 31522005–31522204 Yes [32]
34 PP2447 No 22q13.33 48925974–48926227 No
*Based on Blat (www.genome.ucsc.edu) search of the May 2004 assembly.
doi:10.1371/journal.pone.0002079.t002
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immortalized by SV40. However, the AD12-SV40-immortalized
PWR-1E normal human prostate cell line [16] did not show
increased methylation of these genes (data not shown). Thus,
acquired methylation in the SVHUC cell line could be derived
from repeated passages and selection during cell culture.
Analysis of Primary Prostate Cancer
Based on the CpG island methylation data from the 21-cell
line panel, we selected 8 genes showing dense CpG island
methylation in prostate cancer cell lines and further analyzed
them in 20 primary prostate cancer and paired normal prostate
samples. Compared to adjacent normal prostate, all 8 genes had
significantly higher methylation in prostate cancer by t-test
analysis (P,0.001 for NKX2-5; P,0.001 for SPOCK2;
P=0.004 for GALR2; P,0.001 for CLSTN1; P,0.001 for
NSE1; P,0.001 for DPYS; P=0.019 for FOXN4; P,0.001 for
SLC16A12) (Figure 3B, 4A and Table S2). FOXN4 and GALR2
were relatively rarely methylated while the other 6 genes showed
remarkably increased methylation levels. Of note, NSE1 and
DPYS also showed some degree of methylation in normal
prostate (average 1064% for NSE1 and average 2469% for
DPYS). The combination of DPYS or NSE1 hypermethylation
showed a sensitivity of 80%, specificity of 95% and accuracy of
95% and the combination of NSE1 or SPOCK2 hypermethyla-
tion showed a sensitivity of 80%, specificity of 95% and
accuracy of 96% in differentiating prostate cancer from normal
(Table 3).
Analysis of Methylation in Other Cancers
Next, we studied colon cancer and breast cancer. The DNA
hypermethylation status of 9 genes showing dense CpG island
methylation in colon cancer cell lines was further analyzed in 24
primary colon cancer and paired normal colon samples. In a panel
of 20 colon cancer cases, all these genes except IRX5, TFAP2E
and TFAP2C showed significantly higher methylation in cancer by
t-test analysis (P,0.001 for NKX2-5, DPYS SPOCK2, GALR2
and SLC16A12; P=0.008 for FOXN4) (Figure 3C, 4B and Table
S3). Notably, GALR2 and DPYS showed some degree of
methylation in normal colon (average 864% for GALR2 and
average 2165% for DPYS). GALR2 hypermethylation showed a
sensitivity of 85%, specificity of 95% and accuracy of 98% and the
combination of GALR2 or NKX2-5 hypermethylation showed a
sensitivity of 90%, specificity of 95% and accuracy of 96% for
detecting colorectal cancer (Table 3).
As shown in Figure 3D, the DNA hypermethylation status of 7
genes showing dense CpG island methylation in breast cancer cell
lines was analyzed in 24 primary breast cancer and paired normal
breast samples. Compared to adjacent normal breast, all 6 genes
except NKX2-5 showed higher methylation in breast cancer by t-
test analysis (P,0.001 for DPYS and EGFR5 P=0.01 for
SLC16A12; P=0.002 for TOX; P=0.003 for GALR2)
(Figure 3B, 4C and Table S4). NKX2-5 was relatively rarely
methylated while the other 6 genes showed remarkably increased
methylation levels. Of note, EGFR5 showed some degree of
methylation in normal breast (average 17613%). The combina-
tion of EGFR5 or TOX hypermethylation showed a sensitivity of
92%, specificity of 92% and accuracy of 93% and the combination
of DPYS or TOX hypermethylation showed a sensitivity of 88%,
specificity of 96% and accuracy of 91% for detecting breast cancer
(Table 3).
Methylation and Gene Expression
To confirm silencing by DNA methylation, we performed
expression analysis by RT-PCR for eight genes, TFAP2C, NKX2-
5, GALR2, DPYS, TFAP2E, CDEP, SPOCK2, and NSE1
selected based on methylation frequency and potential
function (Figure 5). Most cell lines chosen for analysis had high
methylation level (.50%), and all had very low levels of expression
at baseline. Expression of these genes was easily restored after
treatment with the demethylating agent, 5-azadC in all cases
Figure 1. CpG island map and DNA methylation status of
identified clones. CpG maps of the seventeen genes analyzed in this
study. For each gene, short vertical bars indicate CpG sites. Exon1 is
indicated by black rectangles at the top, whereas location of the MCA-
RDA clones is indicated by red rectangles at the bottom. Arrows point
to known or presumed transcription start sites. Blue bars at the bottom
indicate areas that analyzed by COBRA or pyrosequencing.
doi:10.1371/journal.pone.0002079.g001
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deacetylase inhibitor, TSA alone did not restore gene expression at
TFAP2C, NKX2-5 and NSE1. The other genes showed increased
expression after TSA but to a lesser extent than after 5-azadC
treatment. For 5-azadC and TSA combined treatment, TFAP2C,
TFAP2E, CDEP, SPOCK2 and NSE1 showed synergistic effects
on expression.
Discussion
To isolate novel methylated genes in cancer, we applied MCA-
RDA to prostate cancer cell lines and identified 34 promoter-
associated CpG islands differently methylated compared to normal
control. All of 17 genes investigated had hypermethylation in at
least 2 cell lines of a 21-cell line panel containing prostate cancer,
colon cancer, leukemia, and breast cancer. We thus confirmed that
Figure 2. Representative COBRA and pyrosequencing for GALR2 and TFAP2C. For GALR2 and TFAP2C methylation analyses, we used
COBRA (left panel) and pyrosequencing (right panel). The methylation density of pyrosequencing is presented in the top of each tracing as the
averaged methylation of the CpG sites analyzed. Both methods analyzed almost the same sites in the promoter region as presented in Figure 1. A. In
GALR2 methylation analysis, normal adjacent sample showed 9% methylation by COBRA and 6% by pyrosequencing but tumor sample showed 45%
by COBRA and 42% by pyrosequencing. B. In TFAP2C methylation analysis, normal sample showed 1% methylation by COBRA and 3% methylation
by pyrosequencing but tumor sample showed 61% by COBRA and 64% by pyrosequencing.
doi:10.1371/journal.pone.0002079.g002
Novel Markers for Prostate Ca
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methylated at multiple loci. MCA-RDA with repetitive subtractive
hybridization is, however, labor intensive and costly, and requires
hundreds of clones to be sequenced. A recent improvement was to
couple MCA with microarrays [17] thus improving the yield of the
method. MCA could also potentially be coupled with deep
sequencing technology [18].
In most of the cases, cancer cell lines exhibited higher levels of
CpG island hypermethylation than primary cancers as previously
shown [19]. For example, most prostate and colon cancer cell lines
showed hypermethylation at FOXN4 and GALR2, but primary
prostate cancers showed lower frequency methylation compared to
primary colon cancer. Therefore, it seems likely that part of the
hypermethylation events displayed in cancer cell lines come from
Figure 3. Heat map of DNA methylation profiling of identified clones by MCA-RDA. The bottom red-scale bar refers to the degree of
methylation as measured by COBRA and/or pyrosequencing. NL represents normal leukocyte. A. All of the 17 genes investigated were methylated in
at least 2 cell lines of a 21-cell line panel investigated. B. Methylation map for 8 genes studied in twenty primary prostate cancers (T) and paired
normal (N) prostate samples. C. Methylation map for 9 genes studied in twenty primary colon cancers (T) and paired normal (N) colon samples. D.
Methylation map of 7 genes in twenty-four breast cancers (T) and paired normal (N) samples. Pat.; patient samples.
doi:10.1371/journal.pone.0002079.g003
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addition, compared to an immortalized cell line (PWR-1E) that
was established in 1996, SVHUC cell line, established in 1987
[20], showed increased methylation of some genes, likely derived
from reiterated passages in cell culture. Nevertheless, our results
also show that cancer cell lines maintain hypermethylation
specificity because most methylation events in cancer cell lines
also occur in some primary cancers.
DNA methylation provides a powerful diagnostic biomarker for
cancer. It was recently estimated that hypermethylation is one
order of magnitude more frequent than mutation in cancer [21]
DNA methylation could be useful for disease diagnosis in
uncertain cancer, or for screening in body fluids [22]. In this
study, we identify high sensitivity markers for prostate cancer,
colon cancer and breast cancer, which could be worth testing in
appropriate surrogate samples (e.g. ejaculate, urine for prostate
cancer; serum, stool for colon cancer; nipple aspirate for breast
cancer etc.). It is also interesting that some of the genes show
Figure 4. Scatter plots of methylation analysis in primary
prostate cancer (A), colorectal cancer (B) and breast cancer (C).
N and T represent tumor and adjacent normal. *Significantly different
from normal adjacent samples, P,0.05.
doi:10.1371/journal.pone.0002079.g004
Table 3. Diagnostic information of single or combined
candidate biomarkers isolated by MCA-RDA.
Biomarker % Sensitivity % Specificity % Accuracy
Prostate Ca.
NKX2-5 55 95 79
CALSTN1 65 95 92
SPOCK2 60 95 80
NSE1 65 95 95
SLC16A12 55 95 90
FOXN4 40 95 69
GALR2 35 95 78
DPYS 80 90 91
DPYS or NKX2-5 85 95 90
CALSTN1 or DYPS 75 95 94
NSE1 or DPYS 80 95 95
NSE1 or SPOCK2 80 95 96
SLC16A12 or DPYS 75 95 93
Colorectal Ca.
NKX2-5 70 95 71
SPOCK2 60 95 76
GALR2 85 95 98
FOXN4 35 100 70
TFAP2C 30 95 58
DPYS 80 90 91
SLC16A12 85 95 91
NKX2-5 or SLC16A12 90 95 92
SPOCK2 or SLC16A12 90 95 94
GALR2 or NKX2-5 90 95 96
NKX2-5 or SPOCK2 80 95 89
Breast Ca.
SLC16A12 38 96 64
DPYS 83 96 91
TOX 42 96 63
GALR2 67 88 87
SPOCK2 63 96 73
EGFR5 79 96 83
DPYS or TOX 88 96 91
A16 or SPOCK2 71 96 82
A16 or DPYS 63 96 90
EGFR5 or TOX 92 92 93
The other gene combinations did not improve the sensitivity markedly. The
accuracy of a test is measured by the area under the Receiver Operating
Characateristic (ROC) curve.
doi:10.1371/journal.pone.0002079.t003
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be seen whether this is related to age-dependent methylation
[23,24] or to a field defect specific to patients with cancer [25]. It is
also interesting to note tissue specific differences in methylation.
For example, NKX2-5 is methylated in prostate and colon cancer,
but rarely in breast cancer. GALR2 is hypermethylated in colon
cancer and breast cancer but rarely in prostate cancer. The
mechanisms underlying such differences deserve further investi-
gation.
Our data identified TFAP2C and TFAP2E as potentially
important new targets of transcriptional silencing in colon cancer.
The AP-2 family of transcription factors consists of five
homologous proteins, AP-2a, AP-2b, AP-2c, AP-2d, and AP-2e.
AP-2 transcription factors play important roles in embryonic
development by influencing the differentiation, proliferation, and
survival of cells. The overexpression of AP-2 in HepG2 human
hepatoblastoma and SW480 human colon adenocarcinoma cells
inhibited cell division and colony formation [26]. Importantly, re-
expression of AP-2 in AP-2 negative melanoma cells suppressed
their tumorigenicity and metastatic potential in nude mice [27].
These data suggest that AP-2 transcription factors are involved in
the maintenance of a proliferative and undifferentiated state of
cells, a characteristic not only important to embryonic develop-
ment but also to tumorigenesis.
Some of the other genes identified could also be functionally
important. However, the methylation observed here may also
simply reflect the global redistribution of 5-methylcytosine during
cancer development [28]. Thus, these clones should be function-
ally investigated before conclusions can be made regarding their
role in cancer. In conclusion, our data identify potentially
important new targets of transcriptional silencing in cancer, and
provide new biomarkers that could be useful in screening for
prostate cancer, colon cancer and breast cancer.
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